EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19

Marianna Puccini, Kai Jakobs, Leander Reinshagen, Julian Friebel, Philipp-Alexander Schencke, Emily Ghanbari, Ulf Landmesser, Arash Haghikia iD, Nicolle Kränkel, Ursula Rauch

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24097683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marianna Puccini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, 12203 Berlin, Germany. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic marker of severity. The aim of this study was to evaluate whether galectin-3 is associated with thrombogenicity in COVID-19. Patients with moderate-to-severe COVID-19 (COVpos; n = 55) and patients with acute respiratory diseases, but without COVID-19 (COVneg; n = 35), were included in the study. We measured the amount of galectin-3, as well as other platelet and coagulation markers, and correlated galectin-3 levels with these markers of thrombogenicity and with the SOFA Score values. We found that galectin-3 levels, as well as von Willebrand Factor (vWF), antithrombin and tissue plasminogen activator levels, were higher in the COVpos than they were in the COVneg cohort. Galectin-3 correlated positively with vWF, antithrombin and D-dimer in the COVpos cohort, but not in the COVneg cohort. Moreover, galactin-3 correlated also with clinical disease severity, as measured by the SOFA Score. In patients with acute respiratory diseases, galectin-3 can be considered as a marker not only for disease severity, but also for increased hypercoagulability. Whether galectin-3 might be a useful therapeutic target in COVID-19 needs to be assessed in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansAntithrombinsGalectin 3Tissue Plasminogen Activatorvon Willebrand FactorBlood ProteinsGalectins

Stichwörter der Autor:innen

COVID-19galectin-3increased thrombogenicityplatelet activation

Substanzen

AntithrombinsGalectin 3Tissue Plasminogen Activatorvon Willebrand FactorLGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, 12203 Berlin, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10178 Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 10178 Berlin, Germany.

ORCID-Profile: Arash Haghikia

Zitieren

APA

Puccini, M., Jakobs, K., Reinshagen, L., Friebel, J., Schencke, P. A., Ghanbari, E., Landmesser, U., Haghikia, A., Kränkel, N., & Rauch, U. (2023). Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097683

Vancouver

Puccini M, Jakobs K, Reinshagen L, Friebel J, Schencke PA, Ghanbari E, et al. Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097683

BibTeX
@article{Puccini2023,
  author = {Puccini, Marianna and Jakobs, Kai and Reinshagen, Leander and Friebel, Julian and Schencke, Philipp-Alexander and Ghanbari, Emily and Landmesser, Ulf and Haghikia, Arash and Kränkel, Nicolle and Rauch, Ursula},
  title = {Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24097683}
}
Kostenlos starten →